secwatch.observer — SEC 8-K summary
======================================

Issuer:     Nuvation Bio Inc. (NUVB)
CIK:        0001811063
Form:       8-K/A
Filed at:   2024-06-20T23:59:59+00:00
Accession:  0001193125-24-164595
Event type: other_material
Sentiment:  positive
Materiality: 0.80
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Nuvation Bio files 8-K/A with AnHeart financials and updated taletrectinib clinical data
--------------------------------------------------------------------------------

- Acquired AnHeart in Apr 2024; audited AnHeart FY2023 and FY2022 financials included.
- Taletrectinib TRUST-I: 90.6% cORR in TKI-naive ROS1+ NSCLC; median PFS not reached at 23.5 mo f/u.
- Intracranial cORR 87.5% (TKI-naive) and 73.3% (TKI-pretreated) in TRUST-I; low neuro TEAEs.
- NDA accepted in China with priority review for taletrectinib; Breakthrough Therapy in US and China.
- Innovent out-license: $55M received; up to $29M regulatory + $105M commercial milestones.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1811063/000119312524164595/0001193125-24-164595-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1811063/000119312524164595/d837366d8ka.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-164595

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer